cushieblog.com
A Phase III Study of Osilodrostat to Treat Cushing’s Disease
CLCI699C2302: A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study with an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients wi…